Anna van der Voort

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 413 citations · Full text

Breast Oncology, Oncology, Dual Her2 Blockade +7

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer

Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven et al. · JAMA Oncology · 2021 · 130 citations · Full text

Experimental modelling and LPV control of a motion system

M. Steinbuch, René van de Molengraft, Anna van der Voort · 2004 · 78 citations

Experimental Modelling, Motion Control, Engineering +15

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst et al. · The Lancet Oncology · 2024 · 36 citations · Full text

Neoadjuvant Chemotherapy Duration, Breast Oncology, Medical Imaging +10

Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.

Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven et al. · Journal of Clinical Oncology · 2020 · 35 citations

Breast Oncology, Oncology, Health Sciences +13